Ipsen S.A. (OTCMKTS:IPSEY – Get Free Report) shares crossed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $29.95 and traded as high as $30.56. Ipsen shares last traded at $30.51, with a volume of 1,363 shares changing hands.
Ipsen Trading Up 1.4 %
The business’s fifty day moving average is $30.23 and its two-hundred day moving average is $29.95.
Ipsen Company Profile
Ipsen SA operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial.
Read More
- Five stocks we like better than Ipsen
- How to invest in marijuana stocks in 7 steps
- What GTC 2025 Signals for NVIDIA Stock’s Next Big Move
- What Are Trending Stocks? Trending Stocks Explained
- Alphabet’s Officially In A Bear Market—Time To Buy?
- Retail Stocks Investing, Explained
- D-Wave and Quantum Supremacy: Implications For Investors
Receive News & Ratings for Ipsen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ipsen and related companies with MarketBeat.com's FREE daily email newsletter.